Ubs Asset Management Americas Inc Regeneron Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$277 Billion
Q1 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 684,564 shares of REGN stock, worth $719 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

684,564

Previous 666,381 2.73%

Holding current value

$719 Million

Previous $585 Million 12.58%

% of portfolio

0.24%

Previous 0.23%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $16.4 Million - $18.1 Million	18,183 Added 2.73%	684,564 $659 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $22.5 Million - $25.6 Million	-29,006 Reduced 4.17%	666,381 $585 Million
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $20.2 Million - $24.7 Million	29,203 Added 4.38%	695,387 $572 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $40 Million - $48.6 Million	58,828 Added 9.69%	666,184 $547 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $4.49 Million - $4.88 Million	6,362 Added 1.06%	607,356 $438 Million

Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $1.47 Million - $1.85 Million	-2,554 Reduced 0.42%	600,994 $414 Million
Q2 2022 Aug 12, 2022	BUY	$548.35 - $738.84 $15 Million - $20.2 Million	27,385 Added 4.75%	603,548 $357 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $18.9 Million - $22.2 Million	-31,755 Reduced 5.22%	576,163 $402 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $45.5 Million - $56.2 Million	83,707 Added 15.97%	607,918 $384 Million
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $28.1 Million - $33.4 Million	-49,007 Reduced 8.55%	524,211 $317 Million
Q2 2021 Aug 16, 2021	SELL	$472.8 - $558.54 $21.3 Million - $25.2 Million	-45,128 Reduced 7.3%	573,218 $320 Million
Q1 2021 May 14, 2021	SELL	$446.73 - $548.2 $11.2 Million - $13.8 Million	-25,096 Reduced 3.9%	618,346 $293 Million
Q4 2020 Mar 01, 2021	BUY	$478.3 - $607.98 $24.5 Million - $31.2 Million	51,243 Added 8.65%	643,442 $311 Million
Q3 2020 Nov 13, 2020	BUY	$544.75 - $658.21 $49.1 Million - $59.3 Million	90,142 Added 17.95%	592,199 $332 Million
Q2 2020 Aug 14, 2020	BUY	$493.32 - $643.92 $82.9 Million - $108 Million	167,966 Added 50.28%	502,057 $313 Million
Q1 2020 May 15, 2020	BUY	$336.18 - $494.43 $955,087 - $1.4 Million	2,841 Added 0.86%	334,091 $163 Million
Q4 2019 Feb 14, 2020	SELL	$274.13 - $376.51 $731,104 - $1 Million	-2,667 Reduced 0.8%	331,250 $124 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $20.5 Million - $23.8 Million	-74,874 Reduced 18.32%	333,917 $92.6 Million
Q2 2019 Aug 15, 2019	SELL	$299.6 - $414.82 $267,243 - $370,019	-892 Reduced 0.22%	408,791 $0
Q1 2019 May 14, 2019	BUY	$372.08 - $439.57 $31.7 Million - $37.5 Million	85,327 Added 26.31%	409,683 $0
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $2.04 Million - $2.45 Million	6,070 Added 1.91%	324,356 $121 Million
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $7.79 Million - $9.06 Million	-22,172 Reduced 6.51%	318,286 $0
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $180,436 - $218,723	-634 Reduced 0.19%	340,458 $0
Q1 2018 May 14, 2018	SELL	$315.82 - $393.78 $67.1 Million - $83.6 Million	-212,409 Reduced 38.38%	341,092 $0
Q4 2017 Feb 09, 2018	BUY	$358.63 - $469.95 $95.9 Million - $126 Million	267,442 Added 93.49%	553,501 $0
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $123 Million - $144 Million	286,059	286,059 $0

Others Institutions Holding REGN

# of Institutions

1,424

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $113B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Regeneron Pharmaceuticals, Inc. Transaction History